RC48 targets HER2 on tumor cells; after internalization it releases MMAE, which binds the vinca domain of beta-tubulin to disrupt microtubules and induce apoptosis. Beta-tubulin expression alone does not confer targeting; killing requires HER2-mediated delivery (with possible bystander killing from diffused payload).